INDIANAPOLIS — Eli Lilly & Company and Novo Nordisk announced they are cutting prices on their weight loss drugs in a deal cut with the White House.

”It's truly an honor to be here today for this historic step forward to expand access to a class of medications that can fundamentally change to arc of chronic disease in our country,” said Lilly President & CEO David Ricks in an Oval Office announcement.

President Trump said the companies have agreed to cap their costs for the popular Novo Nordisk drug Wegovy and the Lilly drug Zepbound to $149-$245 per month and the medications will be made available to Medicaid and Medicare patients.

”It’s a great day for American health and health care and for all of American patients,” said Trump.

”Eli Lilly and Novo Nordisk are committing to offer Ze

See Full Page